Hossen Maria Alejandra, Fujii Yoko, Ogawa Masami, Takubo Miho, Tsumuro Tae, Kamei Chiaki
Department of Pharmacology, Faculty of Pharmaceutical Sciences, Okayama University, Tsushima-naka 1-1-1, Okayama 700-8530, Japan.
Int Immunopharmacol. 2005 Jul;5(7-8):1331-6. doi: 10.1016/j.intimp.2005.02.004. Epub 2005 Mar 9.
To confirm the effectiveness of loratadine for relieving pruritus in atopic dermatitis, we examined the effect of this drug using animal models of atopic dermatitis associated pruritus in ICR and hairless mice. As for the results, in ICR mice, single oral administration of loratadine at a dose of 5 or 10 mg/kg significantly inhibited the dorsal scratching behavior induced by histamine or an antigen, and the effect of loratadine was more potent than that of fexofenadine and chlorpheniramine. In hairless mice, oral administration of loratadine at a dose of 10 mg/kg for 6 days significantly inhibited the facial scratching behavior induced by the feeding of a low magnesium diet. Furthermore, oral administration of loratadine at a dose of 10 mg/kg for 7 days also significantly inhibited the histamine-induced scratching behavior in the same animals. These results indicate that loratadine may be effective in preventing pruritus associated with atopic dermatitis.
为证实氯雷他定缓解特应性皮炎瘙痒的有效性,我们使用ICR小鼠和无毛小鼠的特应性皮炎相关瘙痒动物模型研究了该药的效果。至于结果,在ICR小鼠中,单次口服5或10 mg/kg剂量的氯雷他定可显著抑制组胺或抗原诱导的背部搔抓行为,且氯雷他定的效果比非索非那定和氯苯那敏更强。在无毛小鼠中,口服10 mg/kg剂量的氯雷他定6天可显著抑制低镁饮食喂养诱导的面部搔抓行为。此外,口服10 mg/kg剂量的氯雷他定7天也可显著抑制同一动物中组胺诱导的搔抓行为。这些结果表明氯雷他定可能对预防特应性皮炎相关瘙痒有效。